Good MorningEquity markets shrugged off the risk of a widening Middle Eastern conflict in favor of the interest rate and earnings outlook. With interest rates falling and expected to continue falling in 2025, S&P 500 earnings will continue to grow and build value for investors. In this scenario, the market can continue to rise indefinitely, and new highs will likely occur as the quarters progress. The technical target is now 6,000 and may be reached by year's end.
This week's risk is the CPI report on Thursday. Analysts forecast headline inflation to cool compared to last month and last year, keeping the FOMC on pace to cut rates again this year. The risk is two-fold: cooler-than-expected data could raise fears of a recession, while hotter-than-expected data will keep the FOMC from cutting as aggressively as indicated. The takeaway for investors is that S&P 500 volatility will remain high for the foreseeable future. Featured: The case for trading fewer setups, not more (Ad) 
|
Medical | |
The medical device market, a powerhouse sector, is projected to exceed $600 billion by 2025. This growth is fueled by a combination of factors, including an aging population, rising healthcare costs, and rapid technological advancements powered by advanced artificial intelligence (AI) and biotechn... Read the Full Story |
|
From Our Partners | | Oracle runs 15,000 stocks through the same filter every single day, scanning for precise setups before the opening bell - no emotion, no guesswork.
Tim Bohen, Lead Trainer at StocksToTrade, is walking through this week's flagged setups and showing exactly how the scanner works in a live training right now. | | Watch the scanner in action and join the live training now |
|
Technology | |
Momentum trading involves buying rising stocks with the idea that they will continue rising. While reminiscent of the greater fools theory, momentum trading is more than buying high and selling high. Good momentum trades combine factors that help ensure the market is bullish and capable of continu... Read the Full Story |
|
Consumer Discretionary | |
Every once in a while, a few stocks come under attack from short-selling firms or, essentially, by anyone that doesn’t align with that stock’s business or interests. It is tricky for retail investors to figure out whether short reports and attacks have any traction since they can often... Read the Full Story |
|
From Our Partners | | Every morning before the market opens, a scanner called Oracle runs through 15,000 stocks and scores the setups — so there's already a plan in place by 6:15 a.m.
Lead Trainer Tim Bohen of StocksToTrade is walking through exactly how Oracle works and how regular traders are using it in a training running right now. | | Watch the Oracle training now and see how the scanner works |
|
Markets | |
Though it hasn’t been without its ups and downs, Apple Inc’s (NASDAQ: AAPL) stock has effectively been trading sideways since July. In fact, the tech titan’s shares closed Tuesday’s session at the same price they were just one week before they popped to their last all-time ... Read the Full Story |
|
Aerospace | |
The aerospace and defense industry has been a sustained beacon of strength in an otherwise volatile market. With geopolitical tensions escalating, including the ongoing Russia-Ukraine war and conflicts in the Middle East, the sector has steadily risen with momentum. Two giants in the industry, Loc... Read the Full Story |
|
From Our Partners | | The U.S. government has taken roughly a 10% stake in Intel, negotiated a 15% cut of Nvidia and AMD chip sales to China, and reportedly received a 5% ownership offer - worth around $40 billion - from the most valuable AI company on earth.
Porter Stansberry calls it the New U.S.A.I. - a state-backed arrangement where Washington and a handful of tech giants are fused at the balance sheet. A small number of companies get pulled inside. Everyone else gets frozen out, including names sitting in your index fund right now. | | Watch the documentary to see which companies are on the right side |
|
Consumer Staples | |
There is a significant shift in institutional activity for Helen of Troy (NASDAQ: HELE) shares. The institutions shifted from selling to buying in Q3, creating a solid tailwind due to the high interest. Institutions own nearly 99% of this stock, leaving less than 1.5% for insiders, retail investor... Read the Full Story |
|
Finance | |
It might be surprising for some to hear that 2024 has been a great year for stocks in the insurance industry. In fact, every single large-cap insurance stock in the United States and Canada trading region has a positive return this year. Additionally, the iShares U.S. Insurance ETF (NYSEARCA: IAK)... Read the Full Story |
|
Retail/Wholesale | |
The market’s price action and attention are making a new shift this quarter. For most of 2024, everyone wanted to find the next best thing in the United States technology sector, as the semiconductor industry saw massive rallies in shares of NVIDIA Co. (NASDAQ: NVDA). However, it seems that ... Read the Full Story |
|
Medical | |
Skye Bioscience (NASDAQ: SKYE) is a micro-cap pharmaceutical company that is striving to become the next big thing in the weight loss drug space. The massive success of glucagon-like peptide-1 (GLP-1) agonist drugs sold by Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) has prompted Wall Stre... Read the Full Story |
|
Markets | |
Driven by demand from cloud computing and AI, semiconductor sales have skyrocketed in recent months as pressure due to supply chain concerns and inflation has eased. The specialized chips that power these popular technologies are in such high demand that makers of these products now represent thre... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel. | | View Today's Stock Pick |
|
